Allovir Inc reports results for the quarter ended in September - Earnings Summary

Kalaris Therapeutics

03/11/2022 14:27

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 50
cents​​ per share for the quarter ended in September. The mean
expectation of four analysts for the quarter was for a loss
of 53 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss
of 50
cents​.
    * The mean earnings estimate of analysts had risen by
about 13.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Allovir Inc shares had fallen by 10.9% this quarter and
lost 45.7% so far this year.
    * The company reported a quarterly loss of $42.07 million.
    * Wall Street's median 12-month price target for Allovir Inc
is
$26.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 02:27 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.53          -0.50          Beat
 Jun. 30 2022      -0.73          -0.69          Beat
 Mar. 31 2022      -0.80          -0.69          Beat
 Dec. 31 2021      -0.81          -0.92          Missed